Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT02500134` - Using AS-OCT to Assess the Role of Age and Region in the Morphology and Epithelial Thickness of Limbus	N/A
	Completed	`NCT04773431` - Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency	Phase 1

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT02500134 - Using AS-OCT to Assess the Role of Age and Region in the Morphology and Epithelial Thickness of Limbus

N/A

Completed

NCT04773431 - Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT02886611
Study type	Observational
Source	Fondation Ophtalmologique Adolphe de Rothschild
Contact	Amélie YAVCHITZ, MD, PhD
Phone	0033148036454
Email	ayavchitz@for.paris
Status	Recruiting
Phase
Start date	December 15, 2015
Completion date	June 2025

Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype Correlation — SILOG

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms